Our experimental monoclonal antibody, Xentuzumab – formerly referred to as BI 836845 – represents a notable initiative by Astellas Pharma targeting the PD-1 receptor. Its progression initially focused on solid https://nicolevhnc163893.pointblog.net/xentuzumab-a-deep-investigation-into-bi-836845-and-its-progress-94478599